Revenue — no API Ninjas consensus estimate for this event
Verdict
Revenue of $28.0 million was a record, up 421% from $5.4 million a year ago and approximately 12.5% from Q1 2026.
Gross profit grew 182% to $5.4 million against that 421% revenue growth — the release attributes the gap to pharmacy mix and pricing concessions on new compounding-pharmacy partnerships.
Net income of $2.5 million and Adjusted EBITDA of $3.2 million were both, in the company's words, relatively consistent with Q1 levels while revenue grew 12.5%.
Fiscal 2026 revenue guidance of approximately $150 million was reaffirmed against $53.0 million of first-half revenue.
Cash of $20.0 million and working capital of $35.0 million at June 30 compare with $15.6 million and $15.7 million at December 31, 2025.
Adjusted Revenue of $30.2 million exceeds the $28.0 million reported: the company adds back deferred business partner contract revenue and app-service gross receipts.
Operating activities consumed approximately $8.7 million of cash in the first half despite $5.1 million of six-month net income.
Pharmacy product sales of $26.2 million against total revenue of $28.0 million carry a target margin of about 20% before discounts and incentives.
Gotchas & watch items
The virtual healthcare / direct-to-consumer segment supplied approximately $22.8 million of the quarter against approximately $0.7 million a year ago — the comparison base is close to nil.
Guidance of approximately $150 million leaves roughly $97 million to come after $53.0 million of first-half revenue.
All figures are reported in Canadian dollars.
Gross profit of $5.4 million on $28.0 million of revenue is the same dollar figure as Q2 2025 revenue itself.